Dolutegravir is a new-generation HIV integrase strand transfer inhibitor used for the treatment of HIV-1 infection in adolescents and adults in combination with other antiretroviral drugs. The article overviews potential use of this recently approved drug. Integrase inhibitors (INIs) represent a class of drugs for the treatment of human immunodeficiency virus (HIV) infected individuals. These have been shown to be highly effective for the treatment of antiretroviral-naive and antiretroviral-experienced subjects, as demonstrated first with raltegravir (RAL) and more recently with elvitegravir (EVG).
Both raltegravir and elvitegravir are preferred agents as part of an antiretroviral regimen. Raltegravir and elvitegravir have a low genetic barrier to resistance. Therefore, there is a need for an INI which should possess a high genetic barrier to resistance and activity with human…
